Select Page

Home / Share Price Target / Pdpl

Parenteral Drugs Share Price Target 2024, 2025, 2026 to 2039 With Charts

Parenteral Drugs

Company LogoSymbol: PDPL
Price: ₹2.9
Exchange: NSE
Healthcare -> Drug Manufacturers—Specialty & Generic
Show Table of Contents

Parenteral Drugs Brief Company Overview

Company Overview: Parenteral Drugs (India) Limited

Incorporated in 1983 and headquartered in Indore, India, Parenteral Drugs (India) Limited is a prominent healthcare company renowned for its extensive range of pharmaceutical products.

Their diverse product portfolio includes:

  • Intravenous infusion
  • Inhalation products
  • Veterinary infusion
  • IV fluids (carbohydrates, electrolytes, diuretics, dialysis and irrigation solutions)
  • Anti-infective and anti-fungal products
  • Oncology and anaesthesia products

Parenteral Drugs (India) Limited has a strong market presence, not only in India but also globally, with exports reaching countries such as Iraq, Yemen, Mozambique, Ghana, Kenya, Vietnam, and Myanmar, among others.

The company is committed to providing high-quality healthcare products and services, adhering to stringent industry standards.


Parenteral Drugs Financial Performance

MetricValueDescription
Market Capital10.1 CroreMarket valuation of Parenteral Drugs's shares.
Revenue (TTM)8.49 CroreTotal revenue generated by Parenteral Drugs over the past twelve months.
Net Income (TTM)-76.36 CroreNet Profit or Loss after all the expenses over the past twelve months.
Operating Margin-1863.35%Income from operations as a percentage of revenue, before taxes and interest.
Profit Margin35.67%Net income as a percentage of revenue, after all expenses.
Revenue Growth
(Quarterly)
-31%Change in revenue compared to the previous quarter.
Debt-to-Equity
(D/E) Ratio
3.59Company's total debt divided by total shareholder equity.
Total Debt107.19 CroreSum of Parenteral Drugs's current & long-term financial obligations.
Total Cash1,000Total amount of liquid funds available to Parenteral Drugs.
Beta0.18Beta is less than 1 indicating that the Parenteral Drugs's price is less volatile than the market.

Is Parenteral Drugs A Good Buy For Long Term?

Parenteral Drugs, with a small market cap and significant debt, presents a risky investment opportunity. Its revenue decline and negative profit margin indicate financial challenges. While it has experienced positive returns over the past three years, it has underperformed over the past five years. Based on this data, it is not a recommended buy for long-term investment.

To predict the Parenteral Drugs's future market prices, we harnessed 2 dynamic approaches:

Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices

Approach 1: Technical Analysis Paired With Price Action

Parenteral Drugs Share Price Target For 2024

Parenteral Drugs Targets For 2024 Chart

The line chart displays the monthly closing prices of Parenteral Drugs with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.

For detailed target and stop loss values for Parenteral Drugs shares in 2024, see the table below.

Parenteral Drugs Share Price Target Table For 2024

Parenteral Drugs's LevelsValueReason/Importance
2024 Target 33.00 (+3.44%)Price Action: Sep 2022 Low
2024 Target 22.93 (+1.03%)Price Action: Chart
2024 Target 12.90 (0%)Fibonacci Extension Level 199%
Current Price2.90Parenteral Drugs's 1 share price as of Thu 21 Nov 2024
Stop Loss 12.90 (0%)Fibonacci Retracement Extended 82.6%
Stop Loss 22.85 (-1.73%)Price Action: Sep 2021 Low
Stop Loss 32.80 (-3.45%)Price Action: Jun 2022 Low

Summary: Parenteral Drugs Share Price Prediction For 2024

In summary, Parenteral Drugs has surged by ₹0.00, achieving a notable +0.00% increase from 1st January 2024 to 21 Nov 2024. Despite the setback, our analysis of Parenteral Drugs for 2024 predicts an additional rise of 0% to 3.44% by the end of 2024 with three potential targets T1: 2.90, T2: 2.93, T3: 3.00. Stop Loss at SL1: 2.90, SL2: 2.85, SL3: 2.80.

Parenteral Drugs has a 52-week high of ₹2.90, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹2.90, a critical support level - think of this as a safety net where the price might stop falling.

After looking at 2024's share price prediction, let's now check what 2025 might hold for Parenteral Drugs.

Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!

Join our WhatsApp group

Join our Telegram group

Your phone number will be HIDDEN to other users.

Parenteral Drugs Share Price Target For 2025

Parenteral Drugs Targets For 2025 Chart

The line chart displays the monthly closing prices of Parenteral Drugs with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.

For detailed target and stop loss values for Parenteral Drugs shares in 2025, see the table below.

Parenteral Drugs Share Price Target Table For 2025

Parenteral Drugs's LevelsValueReason/Importance
2025 Target 33.00 (+3.44%)Price Action: Sep 2022 Low
2025 Target 22.93 (+1.03%)Price Action: Chart
2025 Target 12.90 (0%)Fibonacci Extension Level 199%
Current Price2.90Parenteral Drugs's 1 share price as of Thu 21 Nov 2024
Stop Loss 12.90 (0%)Fibonacci Retracement Extended 82%
Stop Loss 22.85 (-1.73%)Price Action: Sep 2021 Low
Stop Loss 32.80 (-3.45%)Price Action: Jun 2022 Low

Summary: Parenteral Drugs Share Price Prediction For 2025

In summary, Parenteral Drugs has surged by ₹0.00, achieving a notable +0.00% increase from 1st January 2024 to 21 Nov 2024. Despite the setback, our analysis of Parenteral Drugs for 2025 predicts an additional rise of 0% to 3.44% by the end of 2025 with three potential targets T1: 2.90, T2: 2.93, T3: 3.00. Stop Loss at SL1: 2.90, SL2: 2.85, SL3: 2.80.

Parenteral Drugs has a All-Time high of ₹400.00, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹2.90, a critical support level - think of this as a safety net where the price might stop falling.

After looking at 2024's and 2025's share price prediction, you might wonder what are short term targets for Parenteral Drugs, we have created a specific page for that check here: Parenteral Drugs Share Price Target For Tomorrow & Next Week

Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!

Join our WhatsApp group

Join our Telegram group

Your phone number will be HIDDEN to other users.

Approach 2: Machine Learning By Studying Historical Prices

Parenteral Drugs Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039

Parenteral Drugs Targets Chart 2024, 2025, 2026 to 2039

This chart presents a detailed projection of Parenteral Drugs share price predictions from 2024, 2025, 2026 to 2039. This share price Prediction represents a CAGR of 4.66% over the next 15 years.

For complete year by year Parenteral Drugs long term share price target from 2024, 2025 to 2039 check the below table.

Parenteral Drugs Share Price Target Table From 2024, 2025, 2026 to 2039

YearParenteral Drugs TargetYoY Change %
2024₹2.9[Current Price]
2024₹3.3114.13%
2025₹3.1-6.35%
2026₹3.254.83%
2027₹3.548.92%
2028₹4.4425.42%
2029₹4.34-2.03%
2030₹4.01-7.59%
2031₹4.163.48%
2032₹4.487.69%
2033₹5.5624.1%
2034₹5.4-2.88%
2035₹4.94-8.52%
2036₹5.072.63%
2037₹5.426.9%
2038₹6.6823.24%
2039₹6.26-6.29%

Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!

Join our WhatsApp group

Join our Telegram group

Your phone number will be HIDDEN to other users.

Parenteral Drugs Past Performance

PDPL main
Parenteral Drugs has been listed on NSE for more than 14 years.
  • In 2010, Parenteral Drugs opening price was ₹195.08
  • As of Thu 21 Nov 2024 the price stands at ₹2.9.
  • This represents a Compound Annual Growth Rate (CAGR) of -24.47%.
  • In 14 years, an investment of 10,000 would have become ₹148.65.

As we wrap up, we hope you like our study on Parenteral Drugs share price predictions, please kindly note that these forecasts are based on technical analysis, past trends, and machine learning models. They are for educational purposes only, not investment advice.

Show Methodology We Use

Methodology Behind the Prediction

The share price predictions present on our site are derived from a robust model that incorporates multiple economic indicators, technical indicators, company performance metrics, and industry-specific factors.

We have historical share price data of all stocks for which we present targets, so we analyse historical trends from those past data and overlay them with projected market conditions to estimate future share prices of a stock.

For more insights into Parenteral Drugs , explore these additional resources:-

Disclaimer: Information is provided 'as is' and solely for informational and educational purposes, not for trading purposes or advice. We highly recommend to do your own research before making any investment.

About The Author

Nippun

Hi, I’m Nippun, a tech enthusiast from Haryana, India. I have been coding since 2010 and using my coding skills in the share market since 2020. I have been coding scripts in Pinescript that work on Tradingview app/web. I love learning about new technology and applying it to solve real-world problems. Coding and share-market are my passions, and I enjoy finding and fixing bugs in code. I aim to share my skill set and experience that can positively impact society. Feel free to connect with me, and let’s learn from each other. My Twitter